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Abstract
The aim of this study was to analyze whether polymorphisms for the null alleles
of Glutathione S-Transferase Mu-1 (GSTM1), Glutathione S-Transferase Theta-
1 (GSTT1), and a low-activity genetic variation of epoxide hydrolase exon three
(EPHX∗3)affecttheriskofdevelopingpolyneuropathy.Theenzymesofthesegenes
are important in the metabolism of toxic compounds. Seventy-nine patients with
cryptogenic polyneuropathy (equivalent to chronic idiopathic axonal neuropathy)
and 398 controls were tested for the genetic polymorphism. Medical records were
reviewed to collect data regarding clinical ﬁndings at diagnosis, and exposure data
wascollectedviaquestionnaires.Theoddsratios(ORs)forthenullformsofGSTM1
and GSTT1 and the normal activity YY form of EPHX∗3 were close to one except
GSTT1,whichreached1.86.Thehighestriskofpolyneuropathywasfoundinsmok-
erswithGSTT1null,whohada3.7timesincreasedrisk.Interactionsbetweengenes
were analyzed and conﬁrmed the increased OR for GSTT1, which was strongest if
the patients had the low-activity HH form of EPHX∗3 (OR 2.37).Our hypothesis
is that the GSTT1 null polymorphism may be related to an impaired metabolism
of toxic substances that could lead to nerve damage in the peripheral nervous
system.
Introduction
Polyneuropathy is a neurological disorder that is common in
middle and late adulthood. Estimates of its prevalence range
from 2.4% to 8% and depend on the selection of patients,
that is, general population or hospital series, and is even
higher in individuals exposed to various toxins, or patients
with diabetes mellitus (Beghi et al. 1995). Although there are
several known causes of polyneuropathy, the etiology often
remains unknown (Martyn and Hughes 1997) and is then
labeled cryptogenic. The mechanism in those cases is often
considered to be exposure to occupational or environmental
agents, which we have previously investigated (Tondel et al.
2006).Axonopathyisthemostcommonformofpathologyin
toxic neuropathies, but underlying pathologic mechanisms
are unclear. It is believed that failure of axonal transport
results in degeneration of vulnerable distal nerve segments
(Spencer et al. 1979; Grifﬁn and Watson 1988) and when
the process continues, the degeneration proceeds proximally
towards the cell body.
In industrial settings and the general environment, some
compounds are neurotoxic, and frequently affect the periph-
eral nerve (Spencer and Schaumburg 2000). One example is
n-hexane, which accumulates in nerve tissue during chronic
exposure (Feldman 1999). It is known to cause primary
axonal degeneration with secondary demyelination (Chang
et al. 1993).
Biotransformation of exogenous and endogenous com-
poundsmayplayaroleinindividualsusceptibilityduetothe
geneticvariabilityofenzymesinvolvedindetoxiﬁcation.The
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metabolism of biotransformation can be divided into two
phases. In phase 1, the original foreign molecule is altered
by adding a functional group, which can then be conjugated
in phase 2. The conjugated molecule can then be excreted
(Timbrell 2000). Normally, these steps lead to a less toxic
molecule, but in some cases, the opposite occurs.
Epoxide hydrolases (EPHXs) are an example of a phase
1 enzyme system that acts by adding water to the epoxide
(Timbrell2000).Theseenzymesplayanimportantroleinthe
metabolism of exogenous chemicals such as polycyclic aro-
matic hydrocarbons (PAHs) (Omiecinski et al. 1993). Epox-
idescanbedetoxiﬁedpartlybymicrosomalEPHX(mEPHX),
which catalyzes their hydrolysis, thereby yielding the cor-
responding dihydrodiols (Oesch 1973). Although this hy-
drolysis is generally considered to represent a detoxiﬁcation
reaction because less toxic chemicals are produced, some di-
hydrodiolsgeneratedfromPAHsaresubstratesforadditional
metabolic changes to highly toxic, mutagenic, and carcino-
genic polycyclic hydrocarbon diol epoxides. Thus, EPHX∗3
plays the same dual role in detoxiﬁcation and activation of
procarcinogens as found in some cytochrome P450s (Ben-
hamou et al. 1998) and, as a consequence, may also play
an important role in neurotoxicity (Guengerich 1982) and
in drug-related adverse events. Two amino acid polymor-
phismshavebeenidentiﬁedinthecodingregionofexonthree
(EPHX∗3), the tyrosine 113 histidine (Y113H) exchange, re-
sulting in a low activity form of the enzyme (Hassett et al.
1994), which may inﬂuence epoxide deactivation in the cell.
PatientswithLeber’sHereditaryOpticNeuropathy,whowere
homozygous for histidine 113 developed the disease earlier
than those without this genotype (Ishikawa et al. 2005). The
polymorphism in exon four, histidine 139 arginine (H139R,
rs2234922), has been suggested as a high-activity isoform
of mEPHX (Smith and Harrison 1997; Benhamou et al.
1998).
TheglutathioneS-transferases(GST)areafamilyofphase
2 enzymes responsible for the metabolism of a broad range
ofxenobioticsandcarcinogens(Mannervik1985).Theseen-
zymes catalyze the conjugation of glutathione with a wide
variety of organic compounds to form thioethers, a reaction
that is sometimes a step in a detoxiﬁcation process leading
to mercapturic acid formation, a classical excretion prod-
uct of xenobiotics (Mannervik 1985). The GST enzymes
have been shown to protect organisms from reactive oxy-
gen compound damage through their ability to bind with
glutathione (Hayes and Strange 2000). Based on amino acid
sequence similarities and antibody cross-reactivity, the GSTs
are divided into several classes, including mu and theta.
Glutathione S-Transferase Mu-1 (GSTM1) and Glutathione
S-TransferaseTheta-1(GSTT1)arebothpolymorphicinhu-
mans and deletions in the genes result in virtual absence of
enzyme activity, particularly with simultaneous deletions in
bothGSTM1andGSTT1genes(Abu-Ameroetal.2009).The
genetic variations can change an individual’s susceptibility
to carcinogens and toxins as well as affect the toxicity and
efﬁcacy of certain drugs (Ginsberg et al. 2009). The genes
encoding the mu class of enzymes are known to be highly
polymorphic(Xuetal.1998).Theyareinvolvedinthedetox-
iﬁcation of electrophilic compounds, including carcinogens,
therapeutic drugs, environmental toxins, and products of
oxidative stress, by conjugation with glutathione. It has been
reported that individuals with GSTM1 null genotype and
high exposure to solvents are at increased risk of developing
solvent-induced chronic toxic encephalopathy (S¨ oderkvist
et al. 1996) and Parkinson’s disease (Dick et al. 2007). The
GSTT1 gene is situated on chromosome 22. For both GSTT1
and GSTM1, the null genotype has been associated with
an increased risk of optic neuropathies (Abu-Amero et al.
2009) and adverse events to drugs, including cognitive im-
pairment after therapy in patients with medulloblastoma
(Barahmani et al. 2009), but not to Leber’s Hereditary Optic
Neuropathy (Ishikawa et al. 2005) or neuropathy in patients
receiving oxaliplatin-based chemotherapy (Lecomte et al.
2006).
Since activity of these xenobiotic-metabolizing enzymes
generally is necessary to promote efﬁcient detoxiﬁcation,
therebyprotectingthebodyfrominjurycausedbyexposures,
we analyzed whether polymorphisms for the null alleles of
GSTM1 and GSTT1 and a genetic variation of mEPHX (low
activity) affect the risk of developing polyneuropathy.
Materials and Methods
In a previous study of patients with cryptogenic neuropathy,
168 consecutive outpatients from departments of neurology
at three hospitals in two neighboring counties in Sweden
(¨ Osterg¨ otland County, University Hospital, Link¨ oping and
MotalaHospitalandJ¨ onk¨ opingCounty,RyhovCountyHos-
pital, J¨ onk¨ oping) between 40 and 79 years of age at the time
ofdiagnosiswerestudied(Lindhetal.2005).Ethicscommit-
tee approval was obtained to re-review records and contact
these subjects. Medical records were reexamined with a pre-
determined study protocol including symptoms, signs, and
laboratory tests, in order to conﬁrm the correct diagnosis
in each case. Patients with a dominantly demyelinating neu-
ropathy, hereditary neuropathy, or any other identiﬁed cause
of neuropathy were excluded (Lindh et al. 2005).
Of the initial cohort of 168 patients, 158 were still alive,
andtheywereaskedtoparticipateinthestudy.Bloodsamples
were collected from the 79 patients (response rate 50%) who
agreedtoparticipate.Therewere54menand25womenwith
polyneuropathy (mean age 71.0 and 68.5, respectively). The
89 patients who did not participate were slightly older (72.5
vs. 70.2 years old), had higher clinical (1.6 vs. 1.4) and neu-
rophysiological severity (2.0 vs. 1.8), but the differences did
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not reach statistical signiﬁcance, and there was no difference
in sex distribution.
The control group was 398 persons from a population-
based control group from the Swedish part of a Parkinson’s
d i s e a s es t u d yo ft h es a m eg e n e t i cp o l y m o r p h i s m sl i v i n gi n
the same geographic area (Dick et al. 2007). The controls
consisted of 198 men and 200 women (mean age 67.4 and
67.5, respectively). The mean age was slightly higher among
cases than controls (70.2 vs. 67.5 years, P < 0.05).
Casesandcontrolscompletedquestionnairesaboutsmok-
ing status and other exposures including solvent or pesticide
exposure, generalized anesthesia, and drinking water from
privatewellsaspreviouslydescribed(Tondeletal.2006;Dick
et al. 2007).
Theclinicalseverityoftheneurologicconditionwasgraded
based on the functional deﬁcit. Grade 1 (mild) clinical sever-
ity was deﬁned as minor motor and/or sensory symptoms
without functional deﬁcit. Grade 3 was deﬁned as severe
symptoms with functional deﬁcit, including slight ataxia or
at least some need for assistance. Grade 2 or moderate sever-
ity was deﬁned as those symptoms and deﬁcits that were in
between Grades 1 and 3. In the same way, patients were re-
garded as having grade 1 (mild) neurophysiological ﬁndings
if neurography and EMG (electromyography) at diagnosis
showed a slight decrease of Compound Motor Axonal Po-
tentials (CMAP), Sensory Nerve Axonal Potentials (SNAP),
or Conduction Velocity (CV) in at least two nerves. Grade 3
(severe) neurophysiological ﬁndings were deﬁned as loss of
sensory or motor responses in at least two nerves as judged
in a previous study and Grade 2 (moderate) as those neu-
rophysiological ﬁndings in between Grades 1 and 3 (Lindh
et al. 2005).
WholebloodwascollectedandleukocyteDNAwasisolated
with Wizard Genome DNA puriﬁcation kit (Promega Inc.,
Madison, Wisconsin). The GSTM1 and GSTT1 null geno-
types were assessed in a multiplex polymerase chain reaction
(PCR) with β-globin as an internal control gene for a suc-
cessful PCR ampliﬁcation (Arand et al. 1996). The amino
acid polymorphisms in the mEPHX gene (EPHX1 exon
3) were determined by a PCR-RFLP (restriction fragment
lengthpolymorphism)assay(Lancasteretal.1996;Smithand
Harrison 1997). For exon 3, there are three possible geno-
types: YY, YH, and HH. The wild-type normal activity allele
is YY and the low-activity genotype is HH.
The ethics committee at the Faculty of Health Sciences at
Link¨ oping University approved the project.
Statistical methods
The statistical analysis was performed using SPSS version
15. Because neither the controls nor the polyneuropathy
patients were normally distributed regarding age, statistical
analyseswereperformedusinganonparametricmethod;the
Kruskal–Wallis test followed by Mann–Whitney U test for
post hoc analysis (using Bonferoni’s correction for multiple
analyses). The chi-square test was used for categorical vari-
ables.Forgroupswithlessthanﬁverespondents,theanalysis
was performed with Fischer’s exact test. Relative risk was ex-
pressed as odds ratio (OR) with 95% conﬁdence intervals
(CI). Comparisons were considered signiﬁcant if P-values
were<0.05.Thepolymorphismswereanalyzedindependent
of sex, as the genes are located on the autosomes.
Multiplelogisticregressionanalyseswereusedtoobtaines-
timates of ORs for genetic factors adjusting for the following
prespeciﬁed covariates: age, sex, ever used tobacco, solvent
or pesticide exposure, generalized anesthesia, and drinking
water from private wells. Interaction between genes was an-
alyzed with Stata version 11.0.
Results
In total, 79 cases with cryptogenic polyneuropathy and
398 controls were tested for genetic polymorphisms in the
GSTM1, GSTT1, and mEPHX genes. The frequencies of the
different genetic polymorphisms are presented in Table 1.
Among the controls there were signiﬁcantly more persons
with GSTT1 null in women than in men, (P = 0.04), and the
homozygous HH variant in mEPHX was more common in
men (P < 0.01). The other variants did not differ between
men and women. There were no statistically signiﬁcant dif-
ferences between cases and controls in any group.
The OR for the null forms of GSTM1 and GSTT1 and the
YY form of EPHX∗3 were close to one for all polymorphisms
except GSTT1, which reached 1.86. When men and women
were analyzed separately, we found that the OR of EPHX∗3
YH and HH versus YY was 0.7 in men, whereas in women it
was 2.1, almost reaching signiﬁcance (Table 2).
Regarding clinical ﬁndings, 24 patients were considered
to have mild ﬁndings and 39 patients had severe ﬁndings.
No signiﬁcant differences were found between the groups in
clinical or neurophysiological severity at diagnosis except a
tendencyforGSTM1nulltohavemoresevereclinicalﬁndings
than GSTM1 positive cases (mean 1.55 vs. 1.31, P = 0.064).
Axonal neuropathy was observed in 41 patients and com-
bined axonal and demyelinating neuropathy in 19 patients.
Regardingneurophysiologicalﬁndings,twopatientshadpure
motor neuropathy, 13 patients had pure sensory neuropathy,
and 64 patients had a mixed sensorimotor neuropathy. Ge-
netic polymorphisms were not signiﬁcantly related to these
neurographic ﬁndings.
We also investigated the effects of different exposures. In
thecontrolgroup,therewere189(47%)smokersorprevious
smokerscomparedwith43(54%)smokersamongthecrypto-
genic polyneuropathy patients. Exposure to solvents during
work or leisure time was reported by 24 (30%) of the pa-
tientswithcryptogenicpolyneuropathyand132(33%)ofthe
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Table 1. Distribution of genetic polymorphisms in cryptogenic polyneuropathy patients and controls.
Total number of subjects Men Women
Pnp Controls Pnp Controls Pnp Controls
n % n % n % n % n % n %
GSTM1 null 40 50.6 201 50.5 30 55.6 100 50.5 10 40.0 101 50.5
GSTM1 pos 39 49.4 197 49.5 24 44.4 98 49.5 15 60.0 99 49.5
GSTT1 null 7 8.9 61 15.3 3 5.6 23 11.6 4 16.0 38 19.0
GSTT1 pos 72 91.1 337 84.7 51 94.4 175 88.4 21 84.0 162 81.0
EPHX∗3 YH 30 38.0 142 35.7 18 33.3 69 34.8 12 48.0 73 36.5
EPHX∗3 YY 39 49.4 202 50.8 30 55.6 93 47.0 9 36.0 109 54.5
EPHX∗3 HH 10 12.7 54 13.6 6 11.1 36 18.2 4 16.0 18 9.0
In total, 79 cases with polyneuropathy and 398 controls were tested for genetic polymorphisms. In the control population, there were signiﬁcantly
more cases with GSTT1 null in women than in men, and the homozygous HH variant was more common in men. The other polymorphisms did not
differ between men and women. There were no statistically signiﬁcant differences between cases and controls in any group. Pnp = Polyneuropathy.
Table 2. Analysis of genetic factors by case–control status (cases vs. controls).
All subjects Men Women
Genetic Reference Studied
polymorphism group groups OR P Value OR P Value OR P Value
GSTM1 Null Positive 0.99 (0.61–1.61) 1 0.82 (0.45–1.50) 0.54 1.53 (0.66–3.57) 0.40
GSTT1 Null Positive 1.86 (0.82–4.24) 0.16 2.23 (0.64–7.74) 0.31 1.23 (0.40–3.80) 1
EPHX∗3 YY YH 1.09 (0.65–1.84) 0.79 0.81 (0.42–1.57) 0.62 1.99 (0.80–4.50) 0.16
YY HH 0.96 (0.45–2.05) 1 0.52 (0.20–1.35) 0.20 2.69 (0.75–9.67) 0.12
YY YH/HH 1.06 (0.65–1.71) 0.90 0.71 (0.39–1.30) 0.29 2.13 (0.90–5.05) 0.09
Odds ratios with 95% conﬁdence intervals for polymorphisms of GSTM1, GSTT1, and EPHX3 were analyzed in 79 cases of cryptogenic polyneuropathy
(54 men, 25 women) and 398 controls from the general population (198 men, 200 women). The chi-square test was used and the analysis was
completed with Fischer’s exact test in groups with less than ﬁve respondents. Comparisons were considered signiﬁcant if P-values were <0.05.
controls. Exposure to pesticides was reported by eight (10%)
ofthepatientswithcryptogenicpolyneuropathyand29(7%)
of the controls. A total of 59 (74%) of the patients with cryp-
togenic polyneuropathy and 312 (78%) of the controls had
been exposed to generalized anesthesia, and 51 (65%) of
the patients with cryptogenic polyneuropathy and 29 (71%)
of the controls had private water supply for at least a pe-
riod in their life. The OR for cryptogenic polyneuropathy
among exposed individuals are shown in Table 3. GSTT1
nullamongsmokersreachedthehighestOR(3.72,P =0.08),
and EPHX∗3 HH versus YY among solvent exposed had the
lowest OR (0.30, P = 0.14). A logistic regression analysis for
thedifferentpolymorphisms,sex,age,andexposuresdidnot
show any confounding effects except that increasing age and
male sex increased the risk of cryptogenic polyneuropathy.
Interactions between genes were analyzed and conﬁrmed the
increased OR for GSTT1, which was strongest if the patients
had the HH form of EPHX∗3 (OR 2.37).
Discussion
In this epidemiological case–control study of patients with
cryptogenic polyneuropathy, we examined the association of
GSTM1 and GSTT1 null polymorphisms and EPHX1 exon
3 HH polymorphism in relation to several environmental
and chemical exposures. Although we did not ﬁnd any sta-
tistically signiﬁcant increased risk, the GSTT1 null geno-
type was associated with an almost twofold increased risk
of polyneuropathy. Our hypothesis is that the GSTT1 null
polymorphism may be related to an impaired metabolism of
toxic substances and reactive oxygen that could lead to nerve
damage, involving multiple sites along motor and sensory
axons in the peripheral nervous system. This may result in
axonalatrophyoraxonalswelling,leadingto progressivedis-
tal axonal degeneration. The myelin sheath may break down
concomitantlywiththeaxon.Thiscouldcontributeto,ordi-
rectlyresultin,anaxonalorcombinedaxonal-demyelinating
neuropathy.
Components of cigarette smoke are examples of exoge-
nous substrates that are toxic and, furthermore, are subject
tobioactivationandmaybothdirectlyandindirectlybeneu-
rotoxic.Wefoundanearlyfourfoldincreasedriskofpolyneu-
ropathyinGSTT1nullsmokersthatalmostachievedstatisti-
cal signiﬁcance.Teunissenandco-authorsreportedanOR of
2.1 for current smoking in patients with chronic idiopathic
axonal polyneuropathy (Teunissen et al. 2002), and it has
138 c   2011 The Authors. Published by Wiley Periodicals, Inc.J. Lindh et al. Polymorphisms in Patients with Cryptogenic Polyneuropathy
Table 3. Effects of genetic polymorphisms in different exposures (exposed cases and controls).
Genetic polymorphisms Studied groups Exposure Odds ratio P Value
GSTM1 Null versus positive Smoking 1.08 (0.56–2.10) 0.87
GSTT1 Null versus positive Smoking 3.72 (0.85–16.2) 0.08
EPHX∗3 YH versus YY Smoking 1.40 (0.69–2.82) 0.38
HH versus YY Smoking 0.57 (0.18–1.82) 0.44
YH/HH versus YY Smoking 1.14 (0.58–2.22) 0.74
GSTM1 Null versus positive Solvent 0.46 (0.18–1.14) 0.12
GSTT1 Null versus positive Solvent 1.31 (0.28–6.1) 1
EPHX∗3 YH versus YY Solvent 0.72 (0.27–1.91) 0.63
HH versus YY Solvent 0.30 (0.06–1.40) 0.14
YH/HH versus YY Solvent 0.55 (0.22–1.34) 0.27
GSTM1 Null versus positive Pesticides 0.98 (0.19–4.94) 1
GSTT1 Null versus positive Pesticides 0.25 (0.01–4.51) 0.39
EPHX∗3 YH versus YY Pesticides 1.33 (0.24–7.28) 1
HH versus YY Pesticides 0.80 (0.07–9.67) 1
YH/HH versus YY Pesticides 1.18 (0.23–5.89) 1
GSTM1 Null versus positive Generalized anesthesia 1.09 (0.62–1.90) 0.78
GSTT1 Null versus positive Generalized anesthesia 1.05 (0.94–1.17) 0.55
EPHX∗3 YH versus YY Generalized anesthesia 1.10 (0.60–2.11) 0.76
HH versus YY Generalized anesthesia 0.95 (0.39–2.32) 1
YH/HH versus YY Generalized anesthesia 1.06 (0.61–1.85) 0.89
GSTM1 Null versus positive Private water 0.78 (0.43–1.43) 0.45
GSTT1 Null versus positive Private water 1.66 (0.57–4.91) 0.48
EPHX∗3 YH versus YY Private water 1.11 (0.58–2.14) 1
HH versus YY Private water 1.01 (0.41–2.50) 1
YH/HH versus YY Private water 1.09 (0.60–1.97) 0.88
Oddsratioswith95%conﬁdenceintervalsforpolymorphismsofGSTM1,GSTT1,andEPHX3aregivenforexposedcasesofcryptogenicpolyneuropathy
and exposed controls from the general population. The chi-square test was used and the analysis was completed with Fischer’s exact test in groups
with less than ﬁve respondents. Comparisons were considered signiﬁcant if P-values were <0.05.
also been found that tobacco use may predispose to earlier
development and more severe symptoms of diabetic neu-
ropathy (Tesfaye et al. 2005). Our data indicate that this risk
mightbeexplainedbysmokerscarryingcertaingeneticpoly-
morphisms leading to impaired detoxiﬁcation of the toxic
compoundsincigarettesmoke.Inastudyofsolvent-induced
chronic toxic encephalopathy, an increased risk ratio of 2.5
for the GSTM1 null genotype was found in smokers and a
risk ratio of 1.5 for the GSTT1 null genotype in the overall
population. In nonsmokers, the GSTM1 null genotype did
not confer any risk for chronic toxic encephalopathy. None
of the studied mEPHX polymorphisms were associated with
anincreasedrisk.Themechanismforthetoxicityofcigarette
smoke on nerves is not known, but it has been speculated
that it is mediated by chemicals in the smoke where PAHs
are regarded as the most important component. Impaired
breakdown of PAHs in persons with the null genotype of
GSTs may lead to increased exposure on nerves and thereby
increased loss of nerves. n-Hexane is another toxic substance
that is present in cigarette smoke and is well known to cause
polyneuropathy (Zhang et al. 2006). However, in our study,
smoking did not increase the risk of polyneuropathy. An en-
hanced negative association between cigarette smoking and
GSTM1 activity has been described in Parkinson’s disease,
which may be mediated by neuroprotective effects of nico-
tine on the dopaminergic system (De Palma et al. 2010).
The frequency of GSTM1 null is about 42–60% in Cau-
casians(Garteetal.2001).Thefrequencyofhomozygousnull
GSTT1 varies greatly with ethnicity and is 10–20% in Cau-
casians (Rebbeck 1997). The EPHX∗3g e n ec a nb ef o u n di n
three different forms, the wild-type/normal activity variant
(YY),heterozygous(YH),orhomozygous/low-activity(HH)
genotypes.InaCaucasianpopulation,about40%ofsubjects
areheterozygousand12%arehomozygousfortheHHgeno-
type (Garte et al. 2001). The frequency of these polymor-
phisms in our study population was similar. No differences
in allele frequencies by age or sex were seen in large studies
(Garteetal.2001).Unfortunatelywehadanimbalanceinour
control group with 19% of the women and 12% of the men
havingtheGSTT1nullpolymorphismand9%ofthewomen
and18%ofthemenhavingtheEPHX∗3HHpolymorphism.
Thus, it is not possible to draw any conclusions about dif-
ferences in risks of cryptogenic polyneuropathy among men
and women separately.
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Individuals carrying genes that code for proteins with lost
or impaired function have an impaired metabolic ability to
eliminatetoxiccompoundsandmaythereforebeatincreased
risk of polyneuropathy. This type of mutation often has an
O Ro f2 – 3f o ri n c r e a s e dr i s kf o rc a n c e r .I no u rg r o u po f
polyneuropathy patients, we found a trend toward lower
OR for the EPHX∗3 gene compared to controls. The total
risk of polyneuropathy probably results from complex inter-
actions of multiple genetic and environmental factors over
time. We have previously conﬁrmed that occupational ex-
posures to Stoddard solvent, petrol exhausts, herbicides, or
hand and foot vibrations generated signiﬁcantly increased
risk of polyneuropathy and new determinants were also in-
dicated, that is, sulphur dioxide, xylene, and methyl ethyl
ketone (Tondel et al. 2006).
Wedidnotﬁndanysigniﬁcantcorrelationbetweenclinical
or neurophysiological severity and genotype except a small
increaseintheseverityofclinicalﬁndingsinGSTM1nullpa-
tientsthatalmostreachedstatisticalsigniﬁcance.Itispossible
that a correlation might be found if a more sensitive scale for
clinical or neurophysiological severity was used.
A possible reason that we did not ﬁnd any signiﬁcant dif-
ferences is the low number of patients. In a Chinese study of
22casesofpolyneuropathyworkinginaprintingfactoryand
163controls,anassociationwasfoundwithCYP2E1Dra,but
not GSTM1 and GSTT1, indicating that either a more pro-
nounced exposure to a toxic agent is necessary or that other
genes may have greater importance for the development of
polyneuropathy (Zhang et al. 2006). Our study sample con-
sistedofpatientsdiagnosedwithcryptogenicpolyneuropathy
at departments of neurology. It is likely that general practi-
tioners properly diagnosed persons working in an industrial
setting with high exposure to toxic agents or that they were
diagnosed as toxic neuropathies by a neurologist resulting in
an underestimation of the risk of exposure in our study.
T h es o l u t i o nt ot h e s ep r o b l e m sw o u l db et od oaG e n o m e -
WideAssociationStudy(GWAS),whichhasbeenasuccessful
way to ﬁnd new candidate genes in, for instance, Parkinson’s
disease, Alzheimer’s disease (Gandhi and Wood 2010), and
sporadicamyotrophiclateralsclerosis(Shatunovetal.2010).
This would, however, require a very large number of patients
recruited from several countries.
In conclusion, no signiﬁcant correlation was found be-
tween GSTM1, GSTT1, and EPHX1 polymorphisms in pa-
tients with cryptogenic polyneuropathy compared with con-
trols. A strong tendency, however, was seen for the GSTT1
null phenotype and smoking in these patients compared to
controls (OR 3.7). The GSTT1 null polymorphism may be
related to an impaired metabolism of toxic substances and
reactive oxygen that could lead to nerve damage in the pe-
ripheralnervoussystem.Thiscouldcontributeto,ordirectly
result in an axonal or combined axonal-demyelinating neu-
ropathy.
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